We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray Brands Soars on Reports of Likely US Marijuana Reclassification
Read MoreHide Full Article
Key Takeaways
TLRY rose 44.1% on Friday after reports that an executive order could reclassify marijuana under federal law.
Tilray Brands rallied as the reclassification could ease banking limits, tax burdens and investment barriers.
Before the surge, TLRY was down 36.6% YTD, highlighting how quickly sentiment shifts on reform signals.
Shares of cannabis producer Tilray Brands, Inc. (TLRY - Free Report) surged 44.1% on Friday, Dec. 12, 2025, on reports that President Donald Trump is expected to sign an executive order as early as Monday that would reclassify marijuana under federal law. The rally marked one of TLRY’s strongest single-day gains in years and reignited investor enthusiasm across the battered cannabis sector.
The likely move would represent a significant shift in U.S. drug policy, potentially easing longstanding federal restrictions that have limited access to banking, raised tax burdens and constrained institutional investment for marijuana-related businesses. While details of the executive order have not been officially confirmed, market participants interpreted the reports as a signal that the government may adopt a more permissive regulatory stance toward cannabis.
Tilray, part of the Zacks Medical - Drugs industry and one of the most recognizable cannabis companies, has struggled alongside peers amid persistent losses, pricing pressure and regulatory uncertainty in the United States. In fact, before Friday’s monumental jump, the stock fell 36.6% this year. The prospect of reclassification fueled hopes that U.S. operators could see lower compliance costs and improved profitability, while international companies like Tilray could gain clearer pathways to expand or partner more aggressively in the U.S. market.
The surge in TLRY also lifted other cannabis-related stocks, with investors betting that reclassification could unlock broader reforms over time, including expanded research, easier access to capital, and greater acceptance among mainstream investors. Canopy Growth Corporation (CGC - Free Report) and Aurora Cannabis Inc. (ACB - Free Report) , two much smaller peers from the same industry, jumped 54% and 18.7%, respectively, in the session. While TLRY and CGC carry a Zacks Rank #3 (Hold), ACB has a Zacks Rank #4 (Sell).
Despite Friday’s rally, the sector remains highly volatile and dependent on follow-through from policymakers. Until the executive order is formally signed and its implications fully outlined, uncertainty will continue to hang over cannabis stocks. Still, the sharp jump in Tilray shares highlighted how sensitive the industry remains to any sign of federal reform, and how quickly sentiment can shift on the prospect of meaningful regulatory change.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tilray Brands Soars on Reports of Likely US Marijuana Reclassification
Key Takeaways
Shares of cannabis producer Tilray Brands, Inc. (TLRY - Free Report) surged 44.1% on Friday, Dec. 12, 2025, on reports that President Donald Trump is expected to sign an executive order as early as Monday that would reclassify marijuana under federal law. The rally marked one of TLRY’s strongest single-day gains in years and reignited investor enthusiasm across the battered cannabis sector.
The likely move would represent a significant shift in U.S. drug policy, potentially easing longstanding federal restrictions that have limited access to banking, raised tax burdens and constrained institutional investment for marijuana-related businesses. While details of the executive order have not been officially confirmed, market participants interpreted the reports as a signal that the government may adopt a more permissive regulatory stance toward cannabis.
Tilray, part of the Zacks Medical - Drugs industry and one of the most recognizable cannabis companies, has struggled alongside peers amid persistent losses, pricing pressure and regulatory uncertainty in the United States. In fact, before Friday’s monumental jump, the stock fell 36.6% this year. The prospect of reclassification fueled hopes that U.S. operators could see lower compliance costs and improved profitability, while international companies like Tilray could gain clearer pathways to expand or partner more aggressively in the U.S. market.
The surge in TLRY also lifted other cannabis-related stocks, with investors betting that reclassification could unlock broader reforms over time, including expanded research, easier access to capital, and greater acceptance among mainstream investors. Canopy Growth Corporation (CGC - Free Report) and Aurora Cannabis Inc. (ACB - Free Report) , two much smaller peers from the same industry, jumped 54% and 18.7%, respectively, in the session. While TLRY and CGC carry a Zacks Rank #3 (Hold), ACB has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Despite Friday’s rally, the sector remains highly volatile and dependent on follow-through from policymakers. Until the executive order is formally signed and its implications fully outlined, uncertainty will continue to hang over cannabis stocks. Still, the sharp jump in Tilray shares highlighted how sensitive the industry remains to any sign of federal reform, and how quickly sentiment can shift on the prospect of meaningful regulatory change.